1h Free Analyst Time
The publisher has been monitoring the cancer therapies market in Europe and it is poised to grow by $34.71 bn during 2022-2026 progressing at a CAGR of 7.92% during the forecast period. The report on the cancer therapies market in Europe provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increased prevalence of cancer and the introduction of combination therapies.
The cancer therapies market in Europe analysis includes the type segment and geographic landscape.
The cancer therapies market in Europe is segmented as below:
By Type
- Chemotherapy
- Targeted therapy
- Immunotherapy
- Others
By Geographical Landscape
- Germany
- UK
- France
- Italy
- Rest of Europe
This study identifies the increasing awareness about effective therapies in patient population as one of the prime reasons driving the cancer therapies market growth in Europe during the next few years.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. The report on cancer therapies market in Europe covers the following areas:
- Cancer therapies market sizing
- Cancer therapies market forecast
- Cancer therapies market industry analysis
The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading cancer therapies market vendors in Europe that include Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Novartis AG, and Pfizer Inc. Also, the cancer therapies market in Europe analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The publisher's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1. Executive Summary
2. Market Landscape
3. Market Sizing
4. Five Forces Analysis
6. Customer landscape
7. Geographic Landscape
8. Drivers, Challenges, and Trends
9. Vendor Landscape
10. Vendor Analysis
11. Appendix
List of Exhibits
Executive Summary
The publisher announces the Publication of its Research Report - Cancer Therapies Market in Europe 2022-2026The publisher recognizes the following companies as the key players in the cancer therapies market in Europe: Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Novartis AG, and Pfizer Inc.
Commenting on the report, an analyst from the publisher said: 'The latest trend gaining momentum in the market is increasing awareness about effective therapies in patient population.'
According to the report, one of the major drivers for this market is the increased prevalence of cancer.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen Inc.
- AstraZeneca Plc
- Bayer AG
- Bristol Myers Squibb Co.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline Plc
- Merck and Co. Inc.
- Novartis AG
- Pfizer Inc.
